Resources Repository
-
ReviewPublication 2023Handbook of Vaccine Health Economics
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of …
The open-access book, "Handbook of Applied Health Economics in Vaccines," looks at the complexities of vaccine discovery, financing, and distribution. It highlights the inadequacy of standard economic models for vaccines. The book explores alternative principles challenging market-based approaches and equips readers with tools for assessing costs and benefits through practical exercises. It serves as a comprehensive resource for decision-making in vaccine development and distribution and emphasizes the importance of considering broader perspectives beyond economic efficiency.…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Costing Methods | Health Outcomes | Decision Analysis | Benefit-Cost Analysis | Policy/Regulation | Global | Graduate | Doctoral | Professional -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | North America -
ReviewPublication 2018Equity Considerations in CEA: Rotavirus Vaccine in LMIC's
The authors used a systematic review of the literature to identify economic evaluations of rotavirus …
The authors used a systematic review of the literature to identify economic evaluations of rotavirus vaccine in LMICs and assess the extent to which equity was considered in the objectives, analysis, and results. They used equity-related indicators provided in the Guidance on Priority Setting in Health Care (GPS-Health) checklist criteria resulting in 18 unique indicators tracked. The authors found that some articles incorporated the indicators in their model inputs (20%) while the majority (80%) presented…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Infectious Diseases | Social Determinants | Global -
ReviewPublication 2015Economic Evaluation of Diet and Physical Activity to Prevent Type 2 Diabetes: Systematic Review
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes …
Studies indicate that combined diet and physical activity promotion programs can prevent type 2 diabetes among persons at increased risk. This paper systematically evaluates the evidence on cost, cost-effectiveness, and cost–benefit estimates of diet and physical activity promotion programs. English-language studies from high-income countries that provided data on cost, cost-effectiveness, or cost–benefit ratios of diet and physical activity promotion programs with at least 2 sessions over at least 3 months delivered to persons at increased risk…
Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Health Systems | Food/Agriculture | North America | Europe | Asia & Pacific -
ReviewPublication 2013Public Health Economics: Review of Guidance for Economic Evaluation
This is a systematic review of published guidance for the economic evaluation of public health …
This is a systematic review of published guidance for the economic evaluation of public health interventions. Public Health Economics is the science and art of supporting decision making as to how society can use its available resources to advance health, and minimize opportunity cost. In this review, the authors identified 5 international guidance documents, 7 UK guidance documents and 4 documents by individual commentators. The papers reviewed identify the main methodological challenges that face analysts…
Cost-Effectiveness Analysis | Health/Medicine | Science/Technology | Priority Setting/Ethics | Costing Methods | Health Systems | Policy/Regulation | Economics/Finance | Europe -
ReviewPublication 2008Cost-Effectiveness of Vaccination: Review of Modelling Approaches
This review examines the modelling approaches used in cost-effectiveness analyses (CEAs) of vaccination programs. After …
This review examines the modelling approaches used in cost-effectiveness analyses (CEAs) of vaccination programs. After overviewing the key attributes of models used in CEAs, a framework for categorizing theoretical models is presented. Categories are based on three main attributes: static/dynamic; stochastic/deterministic; and aggregate/individual based.
Cost-Effectiveness Analysis | Health/Medicine | Science/Technology | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Dynamic Simulation | Infectious Diseases | Global -
ReviewPublication 2006Ethical Issues in Resource Allocation, Research, and New Product Development
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care …
Ethical dilemmas arising in setting priorities among interventions and among individuals in need of care are most acute when needs are great and resources few. This chapter from the Disease Control Priorities in Developing Countries 2nd edition addresses some of these concerns, identifying some of the principal ethical issues that arise in the development and allocation of effective interventions for developing countries and discussing some alternative resolutions. Resource allocation in health and elsewhere should satisfy two main…
Cost-Effectiveness Analysis | Health/Medicine | Science/Technology | Preferences/Values | Priority Setting/Ethics | Culture/Society | Government/Law -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Cost-Effectiveness Analysis | Health/Medicine | Science/Technology | Mathematical Models | Decision Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | North America